华海药业：获得马来酸氟伏沙明片《药品注册证书》

Core Viewpoint - Huahai Pharmaceutical has received approval from the National Medical Products Administration for the registration of Fluvoxamine Maleate Tablets, which are indicated for the treatment of depression and obsessive-compulsive disorder [1] Group 1: Product Approval - The approved product is classified as a Class 4 chemical drug with a specification of 50mg [1] - The approval is seen as a significant step as it is equivalent to passing the consistency evaluation, which will enhance the company's product line and competitiveness [1] Group 2: Market Potential - According to the forecast from the China Insights Consultancy, the domestic market sales for this drug are expected to reach approximately 350 million yuan in the first half of 2025 [1] Group 3: Investment and Development - The company has invested around 4.39 million yuan in the research and development of this drug to date [1] Group 4: Market and Policy Risks - The production and sales of the approved product may be influenced by various factors, including policies and market conditions [1]